Skip to main content

Table 3 Relationship between reproductive factors and breast cancer stratifying by genotype

From: Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project

SNP Genotype Number of deliveriesa Age at menopauseb
   0 1–2 > 2 < 50 years ≥ 50 years
All participants   1 (reference) 0.58 (0.38–0.90) 0.43 (0.27–0.68) 0.77 (0.62–0.96) 1 (reference)
rs2229712 (RPS6KA1 gene) AA genotype (n = 1518) 1 (reference) 0.48 (0.28–0.81) 0.34 (0.19–0.59) 0.64 (0.48–0.86) 1 (reference)
AC or CC genotypes (n = 936) 1 (reference) 0.92 (0.42–1.98) 0.71 (0.31–1.61) 1.06 (0.74–1.54) 1 (reference)
rs1269851 (ATF6B gene) TT genotype (n = 2075) 1 (reference) 0.54 (0.34–0.86) 0.38 (0.23–0.62) 0.73 (0.57–0.93) 1 (reference)
TC or CC genotypes (n = 383) 1 (reference) 0.78 (0.24–2.55) 0.69 (0.20–2.42) 1.16 (0.65–2.07) 1 (reference)
rs2026001 (HSD17B3 gene) GG genotype (n = 896) 1 (reference) 0.48 (0.23–0.98) 0.31 (0.14–0.68) 0.73 (0.50–1.06) 1 (reference)
GT or TT genotypes (n = 1559) 1 (reference) 0.64 (0.37–1.09) 0.50 (0.28–0.89) 0.77 (0.58–1.02) 1 (reference)
rs35652107 (CREB3L1 gene) GG genotype (n = 2163) 1 (reference) 0.68 (0.43–1.07) 0.51 (0.31–0.83) 0.73 (0.58–0.93) 1 (reference)
GT or TT genotypes (n = 291) 1 (reference) 0.23 (0.06–0.88) 0.13 (0.03–0.55) 1.20 (0.61–2.39) 1 (reference)
rs6018027 (SRC gene) TT genotype (n = 1251) 1 (reference) 0.86 (0.47–1.58) 0.52 (0.27–1.00) 0.78 (0.57–1.07) 1 (reference)
CT or CC genotypes (n = 1207) 1 (reference) 0.40 (0.21–0.73) 0.35 (0.18–0.67) 0.77 (0.56–1.07) 1 (reference)
  1. aOdds ratios and 95% confidence intervals adjusted for propensity score, menopausal status, age at menarche, age at first delivery, age at menopause, use of hormonal contraceptives, use of hormone replacement therapy
  2. bodds ratios and 95% confidence intervals adjusted for propensity score, menopausal status, age at menarche, number of deliveries, age at first delivery, use of hormonal contraceptives, use of hormone replacement therapy; estimated in postmenopausal women